Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

7 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Shotgun proteomics of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus

ABSTRACT: Next-generation proteomics of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus for defining the kinetics of whole viral particle antigen production for vaccines. Cells from Day1, Day2, Day3, Day4, Day7 post-infection at two multiplicities of infection.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Chlorocebus Aethiops Aethiops Betacoronavirus Sp.

TISSUE(S): Permanent Cell Line Cell

DISEASE(S): Covid-19

SUBMITTER: Jean ARMENGAUD

LAB HEAD: Jean Armengaud

PROVIDER: PXD018594 | Pride | 2020-06-03

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.

Grenga Lucia L Gallais Fabrice F Pible Olivier O Gaillard Jean-Charles JC Gouveia Duarte D Batina Hélène H Bazaline Niza N Ruat Sylvie S Culotta Karen K Miotello Guylaine G Debroas Stéphanie S Roncato Marie-Anne MA Steinmetz Gérard G Foissard Charlotte C Desplan Anne A Alpha-Bazin Béatrice B Almunia Christine C Gas Fabienne F Bellanger Laurent L Armengaud Jean J

Emerging microbes & infections 20201201 1

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and is continuing to spread rapidly around the globe. No effective vaccine is currently available to prevent COVID-19, and intense efforts are being invested worldwide into vaccine development. In this context, all technology platforms must overcome several challenges resulting from the use of an incompletely characterized new virus. These include finding the right conditions for virus amplification f ...[more]

PMID: 32619390

Similar Datasets

Shotgun proteomics of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus

Project description:Next-generation proteomics of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus for defining the kinetics of whole viral particle antigen production for vaccines. Cells from Day1, Day2, Day3, Day4, Day7 post-infection at two multiplicities of infection.

2020-05-29 | MSV000085510 | MassIVE

Extensive proteomic dataset of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus at Day 4 post-infection

Project description:Next-generation proteomics of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus for defining relevant viral peptides for detection. Cells from Day4 post-infection at 0.01 multiplicity of infection.

2020-05-29 | PXD018804 | Pride

PXD018594-1 Shotgun proteomics of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus [Reanalysis: PXD018594]

2023-03-25 | PXD034694 | JPOST Repository

Extensive proteomic dataset of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus at Day 4 post-infection

2020-05-29 | MSV000085509 | MassIVE

Transcriptome analysis to SARS-CoV-2 infection in Vero E6 cells

Project description:RNAseq was used to identify host and viral transcriptome changes in SARS-CoV-2 infection in Vero E6 cells at 8hpi.

2020-11-21 | GSE161881 | GEO

Gene expression of SARS-CoV-2-infected Vero E6 cells

Project description:We conducted a high-throughput drug repositioning screen using the LOPAC®1280 and the ReFRAME drug libraries to identify existing drugs that harbor antiviral activity against SARS-CoV-2, in a Vero E6 cell-based assay. We additionally performed RNA sequencing on control and SARS-CoV-2 infected Vero E6 cells to study the biological changes after SARS-CoV-2 infection and to elucidate the potential mechanisms underlying the positive hits identified from our high-throughput screen. Vero E6 cells were either mock-infected or infected with SARS-CoV-2 USA-WA1/2020 (MOI = 0.3) with three replicates. Cells were harvested 24 hours after infection, and total RNA was extracted using the Qiagen® RNeasy® Plus Mini Kit. The quality of the extracted RNA was assessed with the Agilent® 2100 Bioanalyzer. Libraries were prepared from total RNA following ribosome RNA depletion using standard protocol according to Illumina®. Total RNA sequencing was then performed on the Illumina® NextSeq system; 150bp paired-end runs were performed and 100 million raw reads per sample were generated.

2020-07-08 | GSE153940 | GEO

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex [Vero E6]

Project description:This study reports a screen to identify putative inhibitors of the eIF4F complex for potential effects on blocking coronavirus replication, using HCoV-OC43 (OC43) infection of Vero E6 cells and the lung epithelial cancer line A549 as models.

2022-12-13 | GSE198399 | GEO

Transcriptomic analysis of the Novel Middle East Respiratory Syndrome Coronavirus (African green monkey, Vero E6 cells)

Project description:We will use the EMC/2012 strain of the novel beta Coronavirus called Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It was initially passaged on Vero E6 cells in Saudi Arabia before being sequenced at the Erasmus Medical College in Rotterdam, Netherlands by Dr Ron Fouchier. We propose to perform a time course of infection of hCoV-EMC on MRC5 cells (Human Lung origin) and Vero cells (African Green Monkey Kidney cells). Both cell lines readily grow and replicate the virus. Importantly these cell lines show signs of Cytopathic effect (CPE), such as cell rounding and release from the petri dish that coincide with time points high virus replication demonstrating the effects of virus replication on the cells. Transcriptomic analysis will be performed after infection with MERS-CoV and SARS-CoV (Urbani strain) to compare the host gene induction that occurs during infection. MRC5 and Vero E6 cells will be infected at an MOI of 0.1 and 3 and RNA harvested from cells at 24 and 48 post infection. RNA will be processed for library creation and sequenced on an Illumina Hiseq. Sequencing reads will be analyzed and compared across the time course and between each virus to identify common response pathways induced during infection as well as unique pathways specific to each virus.

2015-11-19 | E-GEOD-56193 | biostudies-arrayexpress

PXD018804-1 Extensive proteomic dataset of Vero E6 cells infected by Italy-INMI1 SARS-CoV-2 virus at Day 4 post-infection [Reanalysis: PXD018804]

2023-03-25 | PXD034693 | JPOST Repository

Gene expression of SARS-CoV-2-infected Vero E6 cells with remdesivir treatment

Project description:RNA sequencing was performed on control and SARS-CoV-2 infected Vero E6 cells, with or without remdesivir treatment to study the biological changes after SARS-CoV-2 infection and to evaluate the effectiveness of remdesivir on the gene expression level. 500,000 Vero E6 cells were seeded in 6-well plates. The following day, the cell medium was replaced with fresh medium supplemented with either DMSO or 1 µM remdesivir, and cells were either mock-infected or infected with SARS-CoV-2 USA-WA1/2020 (MOI=0.3), with three replicates per experimental condition. Cells were harvested 24 hours after infection, and total RNA was extracted using the Qiagen® RNeasy® Plus Mini Kit. The quality of the extracted RNA was assessed with the Agilent® 2100 Bioanalyzer. Libraries were prepared from total RNA following ribosome RNA depletion using standard protocol according to Illumina®. Total RNA sequencing was then performed on the Illumina® NextSeq system; 150bp paired-end runs were performed and 100 million raw reads per sample were generated.

2021-02-02 | GSE165955 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data